Blackmores boom
October 25, 2012
BLACKMORES’ group sales have
grown an impressive 28% year-on-year
to $85 million during its first
financial quarter ending 30
September.
“Even without the benefit of
BioCeuticals sales, following our
recent acquisition, this would have
been a record sales quarter for the
group,” said Blackmores CEO
Christine Holgate.
The quarter also saw the
company accrue net profit of $7.8
million, a result in line with the
previous corresponding period.
Blackmores has attributed the
strong sales result to a high level of
brand investment in Australia, as
well as continuing growth in Asia
(including its launch into the
Chinese market), and a “pleasing
contribution from BioCeuticals”
(which the company acquired in
July 2012).
“Our high level of marketing
activity in Australia was important
to address the challenging retail
environment,” Holgate said, adding
that the company’s Australian
business grew 9% compared to the
same period in 2011.
Meanwhile in Asia, the company
experienced 14% growth, despite
the challenges from a high Aussie
dollar.
Another strong performer for the
company was NZ, with Holgate
saying that Blackmores’ new NZ
operating model, under which the
company now recognises invoiced
sales to its NZ customers, resulted
in a 175% increase in reported
sales.
Sales in NZ also grew 17% year on
year.
The above article was sent to subscribers in Pharmacy Daily's issue from 25 Oct 12To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Oct 12
